Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating on Mirum Pharamceuticals (NASDAQ: MIRM) after Albireo reported top-line Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE